Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging strategies to overcome resistance to third-generation EGFR inhibitors.

Journal of hematology & oncology - 15 Jul 2022

Shi Kunyu, Wang Guan, Pei Junping, Zhang Jifa, Wang Jiaxing, Ouyang Liang, Wang Yuxi, Li Weimin

Abstract excerpt

Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related to the inhibition of tumor cell proliferation, angiogenesis, invasion, metastasis, and apoptosis. Therefore, EGFR has become an important target for the treatment of cancer, including non-small cell lung cancer, head and neck...

Topics

Join the communities discussing this publication.

Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Drug Resistance, Neoplasm
ErbB Receptors
Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Recurrence, Local

Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 35840984
DOI: 10.1186/s13045-022-01311-6
PMCID: PMC9287895

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging strategies to overcome resistance to third-generation EGFR inhibitors.PMID 35840984Read ↗

The quest to overcome resistance to EGFR-targeted therapies in cancer.Semantic proximity Read ↗

Overcoming Resistance to EGFR Inhibitors in NSCLC.Semantic proximity Read ↗

The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC.Semantic proximity Read ↗

Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?Semantic proximity Read ↗

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.Semantic proximity Read ↗

Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.Semantic proximity Read ↗

Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and ChallengesSemantic proximity Read ↗

Emerging combination therapies to overcome resistance in EGFR-driven tumors.Semantic proximity Read ↗

The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.Semantic proximity Read ↗

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs.Semantic proximity Read ↗

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.